Table 2. Randomized trials comparing platinum-based re-challenge versus single-agent chemotherapy in relapsed SCLC: main outcomes.
| Characteristics | Inoue et al. (10) | Goto et al. (11) | |||
|---|---|---|---|---|---|
| Re-challenge | Amrubicin | Re-challenge | Topotecan | ||
| No. pts | 30 | 27 | 90 | 90 | |
| ORR (%) | 43 | 62 | 84 | 27 | |
| PFS (months) | 5.1 | 5.4 | 5.7 | 3.6 | |
| OS (months) | 14.3 | 14.4 | 18.2 | 12.5 | |
| Grade 3–4 toxicity (%) | |||||
| Neutropenia | 73 | 89 | 84 | 85 | |
| Febrile neutropenia | 0 | 19 | 31 | 7 | |
| Anemia | 20 | 15 | 85 | 27 | |
| Thrombocytopenia | 27 | 15 | 41 | 28 | |
| Hyponatremia | 3 | 4 | 16 | 11 | |
| Hypokalemia | 0 | 7 | 5 | 0 | |
| Diarrhea | 3 | 7 | 8 | 0 | |
| Dose reductions | NR | NR | 50 | 11 | |
| Dose delay | NR | NR | 84 | 71 | |
| Treatment-related death (n) | 0 | 0 | 1 | 2 | |
SCLC, small-cell lung cancer; No. pts, number of patients; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; n, number; NR, not reported.